Paola Favuzza
Parkville, NSW 3052, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
MK-7602: a potent multi-stage dual-targeting antimalarial.
Journal: EBioMedicine
Published: June 23, 2025
Translation of a Human-Based Malaria-on-a-Chip Phenotypic Disease Model for In Vivo Applications.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 21, 2025
The essential malaria protein PfCyRPA targets glycans to invade erythrocytes.
Journal: Cell reports
Published: July 27, 2023
7-N-Substituted-3-oxadiazole Quinolones with Potent Antimalarial Activity Target the Cytochrome bc1 Complex.
Journal: ACS infectious diseases
Published: February 28, 2023
Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4.
Journal: Journal of medicinal chemistry
Published: February 22, 2023
Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362.
Journal: Journal of medicinal chemistry
Published: October 10, 2022
The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.
Journal: ACS medicinal chemistry letters
Published: July 30, 2022
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
Journal: Structure (London, England : 1993)
Published: October 15, 2021
Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity.
Journal: Bioorganic chemistry
Published: July 02, 2021
Property activity refinement of 2-anilino 4-amino substituted quinazolines as antimalarials with fast acting asexual parasite activity.
Journal: Bioorganic chemistry
Published: May 16, 2021
Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.
Journal: Cell host & microbe
Published: October 25, 2019
Last Updated: 09/26/2026